Rituximab-induced serum sickness in multiple sclerosis patients.
Autoimmune disease
Immunology
Multiple sclerosis
Rituximab
Serum sickness
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
25
06
2019
revised:
21
08
2019
accepted:
16
09
2019
pubmed:
23
9
2019
medline:
9
6
2020
entrez:
23
9
2019
Statut:
ppublish
Résumé
Rituximab is a chimeric anti-CD20 monoclonal antibody that is an effective therapy for multiple sclerosis. Rituximab has been associated with the development of serum sickness (type III hypersensitivity) characterized by arthralgia, fever, and rash during the treatment of other conditions, such as rheumatoid arthritis. Here we describe serum sickness associated with rituximab in multiple sclerosis patients and discuss both the management of serum sickness itself and implications for utilizing alternative anti-CD20 monoclonal antibodies for disease management in this patient population.
Identifiants
pubmed: 31542710
pii: S2211-0348(19)30382-7
doi: 10.1016/j.msard.2019.101402
pii:
doi:
Substances chimiques
Immunologic Factors
0
Rituximab
4F4X42SYQ6
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101402Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.